{"id":"W2792666902","doi":"10.1056/nejmoa1713976","title":"Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":909,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Jewish General Hospital","funders":"F. Hoffmann-La Roche; AbbVie","keywords":"Venetoclax; Rituximab; Bendamustine; Medicine; Internal medicine; Chronic lymphocytic leukemia; Oncology; Progression-free survival; Neutropenia; Leukemia; Gastroenterology; Immunology; Lymphoma; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002043694,0.0002980065,0.001091841,0.0007202798,0.0000657077,0.00001401644,0.000374109,0.00022706,0.002002484],"category_scores_gemma":[0.002388845,0.0001833201,0.0001186953,0.0007570903,0.0005672901,0.0001344943,0.00007156521,0.0008903082,0.0001321417],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.1114828,"about_ca_system_score_gemma":0.1008596,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001846669,"about_ca_topic_score_gemma":0.0007024489,"domain_scores_codex":[0.996312,0.000186007,0.001205185,0.000312467,0.001319619,0.0006647208],"domain_scores_gemma":[0.9971814,0.0006482477,0.0004308404,0.0005375281,0.0004559406,0.0007460522],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.0688731,0.0004214616,0.001543372,0.001331182,0.0008930662,0.03416755,0.009186972,0.0007114065,0.03507986,0.0003382762,0.1559497,0.691504],"study_design_scores_gemma":[0.717801,0.01842162,0.001311375,0.004036885,0.000271878,0.02114769,0.0002589937,0.01235506,0.002359828,0.0004063639,0.2213525,0.0002767023],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851534,0.006076059,0.0002027936,0.001835487,0.001321564,0.0003959399,0.000001302925,0.00003659967,0.004976823],"genre_scores_gemma":[0.9770455,0.001385184,0.000537781,0.0007633689,0.01594671,0.000003356137,0.000005141083,0.00005714914,0.004255769],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6912273,"threshold_uncertainty_score":0.9989098,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03256968068832229,"score_gpt":0.3346197826151289,"score_spread":0.3020501019268066,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}